Genmab says J&J not exercising option on HexaBody-CD38
Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...
The Pharma Letter4h
J&J pulls out of HexaBody-CD38 collaboration with Genmab
Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...
Fierce Biotech22h
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
pharmaphorum4h
J&J abandons work with Genmab on Darzalex successor
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...
Genmab Announces Johnson & Johnson Decision Regarding Hexabody®-CD38
Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...
Genmab upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...
William Blair upgrades Genmab with focus now on pipeline
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...